Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Explore linked clinical trials.4 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Clinical Trial of MT200605 for the Treatment of Acute Ischemic Stroke | Acute Ischemic Stroke, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, ischemic stroke, nervous system disorder, stroke disorder, vascular disorder | Recruiting | Phase 2 | 2025-10-03 | NCT07205328 | |
| Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, endocrine system disorder, hyperparathyroidism, kidney disorder, kidney failure, parathyroid gland disorder, secondary hyperparathyroidism, urinary system disorder | Recruiting | Phase 3 | 2025-10-01 | NCT07122401 | |
| Phase I Study of MT1011 Injection in Healthy Subjects | Used in Patients Receiving Anticoagulant Therapy (e.g., Rivaroxaban or Apixaban, Inhibitors of Coagulation Factor Xa) Who Require Reversal of Anticoagulation | Recruiting | Phase 1 | 2025-07-03 | NCT07024160 | |
| Study of MT1013 Injection for the Treatment of Secondary Hyperparathyroidism (SHPT) Patients With Chronic Kidney Disease Undergoing Maintenance Dialysis | endocrine system disorder, hyperparathyroidism, parathyroid gland disorder, secondary hyperparathyroidism | Recruiting | Phase 2 | 2025-05-16 | NCT06976177 |